RNAi Technology Market Size to Reach USD 13.63 Billion by 2035 | SNS Insider

A forecast projects the U.S. RNAi technology market to rise from $1.24B in 2025 to $4.77B by 2035 (about 3.8x), while Europe is expected to grow from $0.93B to $3.42B (about 3.7x). Growth is attributed to expanding RNA-based therapeutic development and increased biotechnology investment.

Analysis

This is a valuation-supportive TAM update, not a near-term earnings catalyst. The public-market winners are the few names that can already show human proof-of-concept and manufacturing leverage; that makes the theme much more relevant for ALNY than for the broader pre-commercial basket. In other words, the market is likely to reward de-risked execution more than “RNAi exposure” as a category.

Second-order, the bigger implication is competitive substitution inside oligo therapeutics: if RNAi keeps proving durable and repeat-dose friendly, capital may rotate away from platforms that still depend on higher-friction delivery or weaker commercial durability. That said, most of the dollar value likely accrues to a narrow set of liver-targeted franchises, while the research-tool and services layer sees only modest volume lift. For CDMO/CRO names, this is a slow-burn demand tailwind, not a rerating event.

Contrarian view: consensus often extrapolates TAM faster than payer willingness and target-density can support. The market could be underestimating how concentrated the eventual profit pool is, which argues against buying a basket of speculative RNAi developers on this headline alone. What would falsify the bullish setup is a lack of label expansion, weaker net pricing, or a financing window that tightens before the next meaningful readout.

Over 1-3 months, expect little direct stock impact absent a catalyst calendar; over 6-18 months, the theme matters if clinical readouts confirm that RNAi can keep taking share in chronic specialty indications without margin erosion. If that happens, the main rerating will be in quality names with existing sales, not in pure concept stocks.

Key Decisions for Investors

• Prefer ALNY as the cleanest public expression of the RNAi theme; add on 5-8% pullbacks only, with a thesis break if revenue growth decelerates or operating margin stalls for two consecutive quarters.
• Avoid initiating a broad biotech basket long solely on this TAM projection; the better trade is a selective quality-over-speculation stance, since most of the implied value is likely to accrue to a few winners rather than the whole space.
• For relative value, consider a small long ALNY / short XBI pair if biotech beta is extended and you want isolated RNAi exposure; cover the short if XBI weakness is driven by macro rather than platform-specific sentiment.
• Set an alert for any capital raises in RNAi development names over the next 1-3 months; a financing cluster would be the first sign that the market is still pricing the area as high-risk optionality, not durable growth.